Dual pathway inhibition as compared to acetylsalicylic acid monotherapy in relation to endothelial function in peripheral artery disease, a phase IV clinical trial

Dual pathway inhibition as compared to acetylsalicylic acid monotherapy in relation to endothelial function in peripheral artery disease, a phase IV clinical trial

ObjectiveDual pathway inhibition (DPI) by combining acetylsalicylic acid (ASA) with low-dose rivaroxaban has been shown to reduce cardiovascular events in patients with peripheral arterial disease (PAD) when compared to ASA monotherapy. A potential explanation is that inhibition of factor Xa improve...

Full description

Bibliographic Details
Main Authors: Loes H. Willems, Dick H. J. Thijssen, Laszlo A. Groh, Nina I. Kooijman, Hugo Ten Cate, Henri M. H. Spronk, A. Rogier T. Donders, Rozemarijn J. van der Vijver-Coppen, Frank van Hoek, Magdolna Nagy, Michel M. P. J. Reijnen, Michiel C. Warlé
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
peripheral arterial disease
aspirin
rivaroxaban
factor Xa inhibitors
endothelial cells
vascular endothelium
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.979819/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.979819/full

Similar Items